Member Info for Yorkshirepragma

Glad this provoked interest…it’s the holy grail for sure, however CEO dialogue very direct on the matter of partner interest within presentation.

Clearly movements.

The platform if it succeeds expands existing drugs ,hence efficacy positive potentially.

Many will be watching as it’s to some extent ‘ de risked’ by above.

If theres a drug portfolio in a BP that can have its work/ market life extended in this mode..then it’s obvious where you’d go,

GLA

Https://merus.nl/about/

In development largely .. bought $8bn.

CEO response within the Q& A to ‘ interest’ , highly relevant , reference partner interest .

Readily envisage partnering and purchase by Annother .

Https://merus.nl/pipeline/

A most relevant comparator … developer with one ( just ) approved !

V, yes illustrates you just don’t know what’s coming and when ?

Aquisitions often done on ego politics … we’re not going to miss this one etc.

CEO indicated they are ‘ busy’ with the deal front .. coukd be tomorrow, next month year or never… tho I doubt the latter.

GLA

Https://www.biopharmadive.com/news/lilly-morphic-acquire-deal-ibd-colitis-crohns/720676/

Https://www.biopharmadive.com/news/merck-verona-acquire-deal-copd-ohtuvayre/752545/

Https://exitwise.com/blog/biotech-valuation

Https://investors.gilead.com/news/news-details/2025/Kite-to-Acquire-Interius-BioTherapeutics-to-Advance-In-Vivo-Platform/default.aspx

See P16 of business update . Not an issue.

Clearly fits with pattern of ‘deals imminent’, as CC has stated , we’re very busy…

Https://interiusbio.com/pipeline/

CC talks of interest… let’s see

Https://www.biopharmadive.com/news/merck-verona-acquire-deal-copd-ohtuvayre/752545/

New product concept , little income,one approval .

Great again today. Reflects stateside interest no doubt with the ‘ high val investors’ having paid the last instalment !

Plus ‘promise’ of action etc

CEO

…., as we enter a pivotal period commercially with multiple catalysts over the coming months.

…& board can’t buy shares due to ‘ knowledge’ in house..

Here we go

Https://www.biopharmadive.com/news/lanova-sino-biopharm-acquisition-china-cancer-drug/753051/

Oncologist info is it’s here to stay .. for the right applications it’s

Https://uk.finance.yahoo.com/news/doxorubicin-global-industry-report-2025-112800977.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAA4qPvk-VfbZWuh2Al-ZJmIX5rfzfyx2AsI4y3OAwpG_Wbs8BKN1cqu6iPDUqWlFPg7jWaOjHxoGtcRvlQJQ1L8ZyHnX8yryLUbwZ6eF4Xev1QUDzv8lp0OxyYgebU2p_JM5WrbFFs9_dhyEcimoGO8Smd2k6JKGzow44aBhYnBN

Share of this will be fine .. sit tight